Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

Bibliographic Details
Main Authors: Ferris, Robert L, Even, Caroline, Haddad, Robert, Tahara, Makoto, Goswami, Trishna, Franks, April, Emeribe, Ugochi, Jarkowski, Anthony, Melillo, Giovanni, Licitra, Lisa
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645286/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645286/

Similar Items